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Abstract
Background: The acceptability and efficacy of a new kit with a new formulation of quinine alkaloids designed for the
intra-rectal administration in the treatment of non-per os malaria was assessed in the peripheral health care system of
Mopti, Mali.
Methods: A single-arm trial was conducted from August 2003 to January 2004. An initial dose of diluted quinine alkaloids
(20 mg/kg Quinimax®) was administered by the intra-rectal route to children with presumptive non per-os malaria at six
peripheral heath care centres. The children were then referred to two referral hospitals where standard inpatient care
including intravenous route were routinely provided. A malaria thick smear was done at inclusion and a second malaria
thick smear after arrival at the referral facility, where a more complete clinical examination and laboratory testing was
done to confirm diagnosis. Confirmed cases of severe malaria or others diseases were treated according to national
treatment guidelines. Cases of non per-os malaria received a second dose of intra rectal quinine alkaloids. Primary
outcome was acceptability of the intra rectal route by children and their parents as well as the ease to handle the kit by
health care workers.
Results: The study included 134 children with a median age of 33 months and 53.7% were male. Most of the children
(67%) and 92% of parents or guardians readily accepted the intra-rectal route; 84% of health care workers found the kit
easy to use. At the peripheral health care centres, 32% of children had a coma score ≤ 3 and this was reduced to 10%
at the referral hospital, following one dose of intra-rectal quinine alkaloids (IRQA). The mean time to availability of oral
route treatment was 1.8 ± 1.1 days. Overall, 73% of cases were confirmed severe malaria and for those the case fatality
rate was 7.2%.
Conclusion: IRQA was well accepted by children, their parents/guardians and by the health workers at peripheral health
facilities in Mopti, Mali. There was also a quick recovery from deep coma and a reduced case fatality rate in severe malaria.
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Background
Clinical malaria can be severe right from its onset. This is
strongly related to individual susceptibilities [1] and often
caused by delayed access to appropriate treatment.
Delayed access to appropriate treatment is known to lead
to increased mortality related to severe malaria [2,3].
In developing countries such as Mali, West Africa, the
health care system is organized to allow treatment of
severe malaria at the hospital level. However, most cases
of malaria occur in rural areas far away from any hospital.
Although local care providers exist in most remote areas
they are not trained to adequately manage severe malaria
episodes. Combined with others factors [4,5], this con-
tributes to a greater delay in accessing adequate treatment
and to the increase of the incidence of severe disease. The
treatment of severe malaria episodes solely at the level of
hospital bears the risk of increasing malaria case fatality
rates. The fact that most of deaths recorded at hospitals
occurred during the first 24 hours after admission [6,7]
highlights the need for earlier actions to reduce case fatal-
ity rates.
Quinine is a critical drug widely used for the treatment of
severe malaria [8]. Despite few cases were P. falciparum
strains with decreased sensitivity to quinine were reported
[9], the drug is recommended by most malaria control
programmes in sub-Saharan Africa.
The use of intra rectal route for administering quinine has
a proven efficacy in the treatment of uncomplicated
malaria in several studies when compared to intra-muscu-
lar or intravenous routes [10]. Intra rectal quinine (IRQA)
was also effective in the treatment of severe malaria and is
an alternative to the intra muscular route, in situation
where intravenous injection cannot be performed [11].
Initial trials have used the bichlorhydrate salt, with pH 2,
which was aggressive for the anal epithelium and had a
reduced bio-availability [12]. Recent studies have used a
new gluconate salt formulation at pH 4.5. The increased
pH resulted into a greater bio-availability and better local
tolerability [13].
The intra rectal route is commonly used in some Malians
villages by mothers for the treatment of others patholo-
gies and by health workers to treat seizures with
diazepam.
The Malian National Malaria Control Program (MNMCP)
decided since 2002 to promote malaria case management
within communities with the aim to allow earlier treat-
ment of malaria clinical episodes. For severe malaria, the
MNMCP chose an emergency one or maximum two doses
of intra rectal quinine at periphery before referral. The
doses would be given outside health care services by
members of the communities (so called "agent relais"
(AR) i.e., community health workers), under the supervi-
sion of the health care personnel working at the primary
contact point between population and health care serv-
ices. In Mali, the first contact with health care services is
organized to occur at the community-based health care
centre. A step-wise approach was adopted to introduce
quinine usage outside health care services. In a first step,
this pilot study of the acceptability of the IRQA was
designed, to assess how the peripheral health care person-
nel and the target population will accept the approach in
the district of Mopti. In a second step would be evaluated
the acceptability and efficacy of the intra-rectal route
when used by ARs. The final step would be the gradual
scale-up of the approach to reach national coverage.
The results of the pilot study that assessed the acceptabil-
ity of the intra rectal gluconate salt quinine given at
periphery by health care agents as an alternative early pre-
transfer treatment strategy of severe malaria in Mopti are
reported in this paper.
Methods
Study site
The study was conducted in the district of Mopti located
in central Mali, an area of seasonal and intense malaria
transmission during the rainy season from July to Novem-
ber. Anopheles gambiae s.l. is the main vector and at peak
transmission the entomologic inoculation rate (EIR) can
reach, 22 infective bites per person and per night [14].
Plasmodium falciparum carriage rate was 40–80% and
malaria accounted for 30% of overall cause of mortality
i.e. the first child killer in the area [14].
Health services are organized in three levels of care in the
region of Mopti. At periphery, the first point of contact
with population is the community-based health care cen-
tre, run by a nurse or a physician and equipped to provide
clinical care with no laboratory support. At the second
level, district hospitals served as referral structures for the
community-based health care centres. Each district hospi-
tal covers a population close to 150,000–200,000 inhab-
itants and provide medical and surgical services including
gynaecology and obstetric with clinical laboratory. At the
third level, the regional hospital located in the city of
Mopti, provides medical, pediatric, general and special-
ized surgical care (including obstetric, ophthalmology
and traumatology) and has capacity for laboratory diag-
nosis and X-rays. Despite its regional vocation the
regional hospital of Mopti (HRM) mainly served as refer-
ral centre for the city of Mopti and its surroundings. Our
study focused on community-based health centres that
refer usually to the HRM and to the district hospital of
Sevare.
The study was conducted among children attending six
peripheral community-based health care centres in four
villages (Medina Coura, Fatoma, Soufroulaye, Socoura),
located at a maximum distance of 12 km from the city of
Mopti. In addition two urban community-based health
care centres both located in the city of Mopti were
included. Children were given an initial dose of IRQA if
they fulfilled the criteria for entry in the study and wereMalaria Journal 2007, 6:68 http://www.malariajournal.com/content/6/1/68
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either referred to the HRM in the case of children from
Medina Coura and the two urban community health care
centres, or to the referral health care centre of Sevare for
children from Fatoma, Socoura and Soufroulaye.
Before the study started, the personnel of the selected
health care centres were trained by the MNMCP and the
team of researchers to standardize their diagnosis of
malaria and to use the IRQA. In addition, the study proto-
col and procedures were explained. The personnel were
instructed to recruit cases from the population that rou-
tinely attended their centres for care and that fulfilled the
entry criteria into the study.
Study patients
Children presenting spontaneously at peripheral health
care centres and looking for care were eligible. Children
were included if they weighed between 5 and 25 kg, were
diagnosed on a clinical basis as a non-per-os malaria epi-
sode, and if their parents/guardians gave consent after
receiving information about the study. The following
exclusion criteria were applied: refusal of parents, associa-
tion with others evident and severe clinical conditions
such as severe malnutrition or meningitis, diarrhoea, pre-
existing anal pathology such as prolapsus, rectitis, anal fis-
sure, chronic diarrhoea, contra-indication to quinine and
uncomplicated malaria episode.
Study design
After an initial clinical assessment, including weighing the
children, blood was collected by finger prick for a malaria
thick smear which was not read immediately. A dose of 20
mg/kg of diluted quinine was administered by rectal
route. Children were observed for 30 minutes and in the
case of early expulsion of the solution, they received a fur-
ther half dose. Afterwards they were transferred to the
referral health care structures, in Sevare or in Mopti. Study
team offered transportation for parents who needed it. At
this level a more complete clinical and laboratory assess-
ment was done. Finger prick blood was collected for a sec-
ond malaria thick smear, determination of blood sugar
and haemoglobin level. Malaria smears were read then
and children were classified into two groups: confirmed
cases of malaria and other diagnosis of children severe
febrile illness (i.e., meningitis or acute respiratory infec-
tion). Children with P. falciparum positive slides and the
criteria for severe malaria defined by the World Health
Organisation (WHO) [8] were considered confirmed
cases of severe malaria and were treated with intravenous
quinine. Confirmed non-per os cases of malaria were
given a second dose of IRQA plus a half dose in case of
early expulsion. Children diagnosed with others diseases
were treated according to national guidelines. All children
were closely followed until the oral route was feasible and
the clinical symptoms resolved.
Study drug
Quinine was used in the form of an emergency paediatric
kit provided by Sanofi-aventis, France. The solution of
Quinimax® is composed of 96.1% of quinine, 2.5% of qui-
nidine gluconate, 0.63% of cinchonine and 0.67% of cin-
chonidine hydrochloride with a pH at 4.5. The mixture of
alkaloids was constituted with the aim to reproduce as
closely as possible, the composition of the natural bark of
quinquina.
The kit was constituted of a 4 ml vial of Quinimax®, a vial
of 13.5 ml purified water and a round-ended syringe spe-
cially designed for rectal administration. The syringe was
marked according to weight and was validated to ensure
that the amount of diluted Quinimax® corresponded to a
given weight of the child and had a content of quinine
corresponding to the dose of 20 mg/kg for that specific
weight. The overall content of the 4 ml vial was 500 mg
gluconate alkaloids of quinine. Just before use, the con-
tent of the vial of Quinimax® was diluted with the 13.5 ml
of purified water giving a final dilution of 28.6 mg/ml.
Only the amount of diluted solution corresponding to the
weight of the child was withdrawn from the vial into the
syringe. The syringe was marked with kilogrammes
instead of millilitres in order to avoid the need for a calcu-
lation of dose at peripheral level and to facilitate the use
of the paediatric kit.
Definitions used
Severe malaria was defined as episodes of fever associated
with P. falciparum parasite in peripheral blood and one of
the following criteria: haemoglobin ≤ 5 g/dl, parasite den-
sity ≥ 100,000/µl, blood sugar ≤ 40 mg/dl, respiratory dis-
tress, seizures in the last 24 hours, coma, or jaundice.
Severe febrile illness associated with persisting vomiting
and inability to drink or eat, in the absence of evident clin-
ical signs or symptoms for a specific diagnosis, was con-
sidered as a non per os malaria episode.
Outcome measurements
Study primary outcome was the acceptability of the intra-
rectal route by children, their parents or guardians and by
health care centres personnel. Acceptability of children
was assessed by the presence of particular reactions during
drug administration, such as pain (manifested by scream-
ing during administration or verbal expression for older
children); presence of particular reactions shortly (30
minutes) after drug administration: local pruritis, pain,
false sensation of stools for older children/important
screaming for younger children/for all children presence
of diarrhoea, blood in stools, inflammation of anal muco-
sis. These particular reactions were assessed by health care
centres personnel at periphery after first administration of
IRQA and at the referral level after the second administra-
tion. Anal margin and stools aspects were directly
observed.Malaria Journal 2007, 6:68 http://www.malariajournal.com/content/6/1/68
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Parents or guardians acceptability was assessed by inter-
view and asking them how they would feel if another
administration of the intra rectal route was proposed to
treat their children.
Health care centre personnel acceptability was assessed by
asking them to fill in the case report form whether it was
easy or uneasy to prepare the solution for intra rectal
administration, to read the marks on the syringe for dos-
ing the amount of solution to be given and to administer/
re administer (in case of early expulsion) the solution.
Secondary outcomes were time to recovery of oral route
and time to clearance of clinical signs/symptoms. These
outcomes were measured twice a day for 7 days after
inclusion into the study.
Data collection and quality control
Before the study started in June 2003, all clinical person-
nel involved in collecting data and administering IRQA
were trained to comply with standardized study proce-
dures for obtaining informed consent, clinical examina-
tion, laboratory testing, filling in of case report forms,
administration of IRQA using the emergency paediatric
kit. Subsequently clinical, behavioural and laboratory
data collected during the study were noted directly into
standardized case report forms. Case report forms were
verified on a daily basis by the study supervisor and three
monitoring visits were conducted during the study to
ensure quality of the data and compliance with protocol.
Data analysis
Data from standardized case report forms were double-
entered with Microsoft ACCESS and database was recon-
ciled. Analysis was done using SPSS 11.0 (Chicago, Illi-
nois). Descriptive analysis was done, computing
percentages and means on main endpoints with 95 confi-
dence intervals. Additional analyses included compari-
sons of proportions using Pearson chi-square and Yates
corrections or Fischer exact tests where indicated. Mc
Nemar chi-square was used for paired data. Means were
compared using Student T test with adjustment to account
for repeated measurements on the same individual.
ANOVA was used to compare means. A difference was
considered significant if p-value was less than 0.05.
Ethical issues
The study protocol was submitted to and approved by the
Faculty of Medicine and Pharmacy Institutional Review
Board before the study commenced. Informed consent
was obtained from parents/guardians of children prior to
their enrolment. The same quality of care was offered to
children in case the parents refused to be part of the study.
Results
Overall 134 patients were enrolled from June 2003 to Jan-
uary 2004. One child died before arriving at the referral
centre; two others died, one forty minutes and the second
three hours and twenty two minutes after arriving at the
referral centre. Out of 133 children that arrived at the
referral centre, 97 (73%) had malaria smear positive for P.
falciparum. Thirty children with negative malaria smears
were diagnosed with others diseases. Sex ratio was 1.13 for
male. The mean age of all children was 36.9 months. The
age of the youngest child was one month and the age of
the oldest was 144 months. Mean weight of children was
11.8 kg with a minimum of 5 kg and a maximum of 23 kg.
All children included received a first dose of IRQA. Early
expulsion of the product after first administration
occurred in 23.1% of the children and required re-admin-
istration of a half dose. A second dose was administered
to 35.1% of the children at the referral unit. For these, the
proportion of early expulsion increased significantly to
40.4% (n = 47, p = 0.023).
Acceptability of the intra rectal route
After the first administration, 32.8% of children expressed
specific reactions (Table 1). Some of the children cried
and were agitated just prior to administration. Few par-
ents (8.2%) were surprised and one parent said that he
Table 1: Acceptability of children and their parents/guardians
All children (N = 134) Positive thick smear (N = 97)
After 1st Intra rectal administration % 95% CI % 95% CI
Child reaction 32.84 25.29–41.12 34.02 25.12–43.86
Parents reaction 8.21 4.39–13.82 7.21 3.21–13.76
Parents accepting a new shot 96.27 91,93–98.62 94.84 88.95–98.09
All children (N = 47) Positive thick smear (N = 35)
After 2nd Intra rectal administration % 95% CI % 95% CI
Child reaction 10,63 4,00–22,01 8,57 2.23–21.58
Parents reaction 2,13 0,11–10,02 2,85 0,14–13,29
Parents accepting a new shot 97,87 89,95–99,89 97,14 86,71–99,86
Overall acceptability of IRQA was high after a second administration.Malaria Journal 2007, 6:68 http://www.malariajournal.com/content/6/1/68
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has no choice face to medical prescription. Most of the
parents would agree to have a second dose of IRQA given
to their child if needed. After a second administration of
intra rectal Quinimax®, 10.6% of children had a specific
reaction consisting of crying and contraction of back mus-
cles prior to administration (Table 1).
The majority of health care personnel found the emer-
gency kit easy to store to prepare and to use. The difficul-
ties evoked by 14.9% of the personnel during
administration of the intra rectal route were due to chil-
dren's agitation during the first administration. At the sec-
ond administration, only 2.1% of the personnel, 7 times
less, reported such difficulties, due to children crying and
contracting back muscles during administration (Table 2).
Clinical tolerance of the IRQA
The most common clinical symptoms presented by chil-
dren following IRQA was the emission of liquid/semi liq-
uid stools (Table 3). Paired analysis showed a significant
three-fold increase in the incidence of liquid/semi liquid
stools after one administration of IRQA. A more impor-
tant increase was observed after the second intra rectal
shot: but this was not associated with more signs of dehy-
dration or more abnormalities of the anal margin. Among
children with skin marks of dehydration (n = 21) at the
referral health care level, 71.4% had liquid stools that
started after the intra rectal administration. Observed
abnormalities of the anal margin consisted of local
inflammation in three children and one case of incipient
prolapsus, at the referral health care unit. All these chil-
dren had a history of diarrhoea in the previous 48 hours.
Parents of one child reported presence of blood in stools
but the evidence did not support this when referral health
care personnel inspected stools. Abnormalities of the anal
margin and presence of blood in the stools reported at the
peripheral health care units were not confirmed by more
experienced paediatric physicians after referral.
Efficacy of IRQA
Overall (n = 124), oral drugs could be administered after
1.8 ± 1.3 days, the minimum being one day and the max-
imum seven days. Confirmed cases of malaria with posi-
tive thick smear that survived (n = 90) had oral route
available after 1.6 ± 0.9 days, with a minimum of one day
and a maximum of five days. The frequency of clinical
symptoms such as coma with Blantyre score ≤ 3 signifi-
cantly decreased at the referral health care unit after IRQA
(Table 5). Overall a case fatality rate of 7.46% 95% CI
[3.85–13.89] was observed. Out of the ten deaths, seven
were associated with signs of respiratory distress. For six
cases biologic parameters were determined and among
those three had blood sugar < 80 mg/dl and hemoglobin
≤ 5 g/dl. At inclusion 20% of children had low blood
sugar level and 90% had mild anaemia (haemoglobin <
11 g/dl).
Discussion
From August 2003 to January 2004 we assessed accepta-
bility of IRQA as treatment of non per os malaria in the
Mopti region, Mali. The framework of routine care offered
at periphery according to the paediatric disease manage-
ment policy of the Malian Ministry of Health was used.
This implementation study showed that administration of
IRQA at peripheral health care centres in Mali was
accepted by 95% of parents and 67% of the children. In
majority, the personnel (85%) found the kit easy to use.
The most common adverse reaction after administration
of IRQA was emission of liquid stools in 75.7% of chil-
dren after the first shot. We observed a case fatality rate of
7.5%.
Children presenting spontaneously at peripheral health
care units were included. In such rural areas, attending the
health care facility happened when all more affordable
means to treat have been used unsuccessfully [5]. This
might have favoured inclusion of more severely ill chil-
dren in our study.
The diagnosis of severe malaria at periphery was based on
symptoms and clinical signs only according to national
guidelines. After referral, almost 30% of cases had nega-
tive blood smear and were diagnosed with others condi-
tions.
In few cases, inclusion criteria were not strictly observed
and some children that had a history of diarrhoea were
Table 2: Easiness of the handling of the paediatric kit by health care personnel
Peripheral care unit 
(N = 134)
Referral care unit (N = 47)
% 95% CI % 95% CI
% of personnel declaring administration is easy 85.07 78.27–90.37 97.87 89.95–99.89
% of personnel declaring storage is easy 100 - 100 -
% of personnel declaring preparation is easy 100 - 100 -
% of personnel declaring reading of weights on syringe is easy 100 - 100 -
According to health care personnel the paediatric kit was easy to use.Malaria Journal 2007, 6:68 http://www.malariajournal.com/content/6/1/68
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included. Abnormalities of anal margins were reported in
these children.
The study might have been biased to include children
with less survival chances than cases of classic non per-os
malaria, in which IRQA could be more efficacious and
better tolerated. But the study population also reflects the
reality of patients to whom IRQA will be administered in
routine circumstances. In routine condition, the likeli-
hood of strict adherence to definitions of non per-os
malaria cases is rather low.
IRQA was well tolerated. Liquid and semi-liquid stools
were the most common adverse reactions observed. A
quarter of patients had liquid stools after first administra-
tion and when they reached the referral care centre the
proportion increased to three quarters. In previous trials
much lower proportion of liquid stools were reported
[15,16]. Such difference can be explained by the differ-
ences in disease severity and clinical presentation at inclu-
sion. Emission of liquid stools was associated with
diminution of body fluids observed by signs of dehydra-
tion on patients' skin. No further impact on child survival
was observed and stools became normal after 25–48
hours. In Gabonese children, severe malaria was associ-
ated with depletion of total body water although, as
observed in Mopti, the diminution of body fluids did not
correlate with severity of disease [17]. In addition a sec-
ond administration of IRQA given to 47 children caused
less frequent liquid stools and no impact on body fluids.
This second dose was better tolerated than the first one.
In cases where abnormalities of anal margins were
reported, the children had anal mucosis injured by previ-
ous episodes of diarrhoea. It emphasizes the need to
respect contra indications of intra rectal route, i.e, to avoid
cases of diarrhoea and lesion of the anal region. In sum-
mary the tolerance profile shown from this study favour
the recommendation to further use IRQA in the treatment
of severe malaria when the intravenous route is not avail-
able.
Health care personnel at peripheral and regional referral
health care unit levels unanimously considered the use of
the kit easy. This will facilitate the subsequent large-scale
implementation of the pre-transfer one or two doses of
IRQA in remote and resource poor areas of Mali under the
auspices of the National Malaria Control Programme.
The sharp reduction in the severity of coma following one
dose and the low case fatality rate observed in such biased
study population confirmed the known efficacy of the
IRQA. The role of confounding factors related to the sin-
gle-arm design is balanced to some extent by the very high
case fatality rate observed in untreated cases of severe
malaria. Our observed case fatality rate,(7.5%) is close to
data reported from Niger [18]. Higher case fatality rates
(16–30%) were observed in similar studies in African hos-
pitals [18,19], while others have reported case fatality
rates as low as 3.5% [6] or 7–13% [7,20]. The above
underlines the difficulties linked to the clinical manage-
ment of severe malaria. Studies have shown that most
deaths from severe malaria occurred in the first 24 hours
Table 3: Clinical tolerance after one or two administrations of IRQA.
After 1st Intra rectal administration Peripheral care unit (N = 130) Referral care unit (N = 130)
%% p - v a l u e
Skin with dehydration marks 3.8 16.2 < 0.01
Abnormal anal margin 2.3 3.1 ns
Blood in stools 0.8 0.8 ns
N = 115 N = 115
Liquid/semi liquid stools 25.2 75.7 < 0.01
After 1st dose After 2nd dose
N = 47 N = 47
%% p - v a l u e
Skin with dehydration marks 4.3 6.4 ns
Abnormal anal margin 2.1 - ns
Blood in stools 0.8 0.8 ns
Liquid/semi liquid stools 19.1 44.7 < 0.01
More children had liquid/semi liquid stools after the first administration of IRQA. The second administration was better tolerated.Malaria Journal 2007, 6:68 http://www.malariajournal.com/content/6/1/68
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after the onset of the disease [6]. In this study too, 7 out of
10 deaths occurred before 24 hours of the child's inclu-
sion. The classical treatment is based on intravenous qui-
nine administered with saline of glucose solution. The
Gabon study [17] showed that administration of fluids
may be harmful and finally the optimal treatment for
severe malaria remains to be codified.
In rural areas in Africa, the rectal route is becoming a
promising alternative. It effectiveness doesn't require co -
administration with fluids. When implemented at the
periphery of a weak health care system, as in Mopti, it
reduces the delay to an effective antimalarial treatment.
Rectal arthemeter has also proven to be well tolerated and
effective in the treatment of severe malaria [21]. However,
quinine has the advantage of being actually available and
known by health care workers and mothers in most Mal-
ian rural areas. Such availability associated to its efficacy
and local tolerance make the intra rectal route for treat-
ment of severe malaria by quinine a precious public
health tools with potential to rapidly decrease the burden
of malaria.
Conclusion
In summary this study showed that IRQA is safe as long as
contra-indications to its use are respected and efficacious
for the initial treatment of severe malaria at peripheral
health care level in Mali. The study supports the further
implementation of the step-wise approach to introduce
quinine usage outside health care services in Mali.
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Convulsions 77.7 74.6 ns
Vomiting 71.5 56.9 0.05
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